170 related articles for article (PubMed ID: 17017874)
1. Synthetic glycopeptides from the mucin family as potential tools in cancer immunotherapy.
Becker T; Dziadek S; Wittrock S; Kunz H
Curr Cancer Drug Targets; 2006 Sep; 6(6):491-517. PubMed ID: 17017874
[TBL] [Abstract][Full Text] [Related]
2. Biomimetic synthesis of the tumor-associated (2,3)-sialyl-T antigen and its incorporation into glycopeptide antigens from the mucins MUC1 and MUC4.
Dziadek S; Brocke C; Kunz H
Chemistry; 2004 Sep; 10(17):4150-62. PubMed ID: 15352098
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of tumor-associated glycopeptide antigens for the development of tumor-selective vaccines.
Dziadek S; Kunz H
Chem Rec; 2004; 3(6):308-21. PubMed ID: 14991920
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of tumor-associated glycopeptide antigens.
Brocke C; Kunz H
Bioorg Med Chem; 2002 Oct; 10(10):3085-112. PubMed ID: 12150854
[TBL] [Abstract][Full Text] [Related]
5. Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.
Pett C; Cai H; Liu J; Palitzsch B; Schorlemer M; Hartmann S; Stergiou N; Lu M; Kunz H; Schmitt E; Westerlind U
Chemistry; 2017 Mar; 23(16):3875-3884. PubMed ID: 27957769
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis of antibody binding to mucin glycopeptides in lung cancer.
Qu J; Yu H; Li F; Zhang C; Trad A; Brooks C; Zhang B; Gong T; Guo Z; Li Y; Ragupathi G; Lou Y; Hwu P; Huang W; Zhou D
Int J Oncol; 2016 Feb; 48(2):587-94. PubMed ID: 26692014
[TBL] [Abstract][Full Text] [Related]
7. Structurally defined synthetic cancer vaccines: analysis of structure, glycosylation and recognition of cancer associated mucin, MUC-1 derived peptides.
Liu X; Sejbal J; Kotovych G; Koganty RR; Reddish MA; Jackson L; Gandhi SS; Mendonca AJ; Longenecker BM
Glycoconj J; 1995 Oct; 12(5):607-17. PubMed ID: 8595249
[TBL] [Abstract][Full Text] [Related]
8. T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity.
Galli-Stampino L; Meinjohanns E; Frische K; Meldal M; Jensen T; Werdelin O; Mouritsen S
Cancer Res; 1997 Aug; 57(15):3214-22. PubMed ID: 9242452
[TBL] [Abstract][Full Text] [Related]
9. Synthetic vaccines from tumor-associated glycopeptide antigens.
Westerlind U; Kunz H
Chimia (Aarau); 2011; 65(1-2):30-4. PubMed ID: 21469441
[TBL] [Abstract][Full Text] [Related]
10. Human lung adenocarcinoma alpha1,3/4-L-fucosyltransferase displays two molecular forms, high substrate affinity for clustered sialyl LacNAc type 1 units as well as mucin core 2 sialyl LacNAc type 2 unit and novel alpha1,2-L-fucosylating activity.
Chandrasekaran EV; Chawda R; Rhodes JM; Xia J; Piskorz C; Matta KL
Glycobiology; 2001 May; 11(5):353-63. PubMed ID: 11425796
[TBL] [Abstract][Full Text] [Related]
11. Synthetic glycopeptides for the development of tumour-selective vaccines.
Kunz H
J Pept Sci; 2003 Sep; 9(9):563-73. PubMed ID: 14552419
[TBL] [Abstract][Full Text] [Related]
12. Chemoenzymatic synthesis of sialylated glycopeptides derived from mucins and T-cell stimulating peptides.
George SK; Schwientek T; Holm B; Reis CA; Clausen H; Kihlberg J
J Am Chem Soc; 2001 Nov; 123(45):11117-25. PubMed ID: 11697954
[TBL] [Abstract][Full Text] [Related]
13. An efficient approach for the characterization of mucin-type glycopeptides: the effect of O-glycosylation on the conformation of synthetic mucin peptides.
Hashimoto R; Fujitani N; Takegawa Y; Kurogochi M; Matsushita T; Naruchi K; Ohyabu N; Hinou H; Gao XD; Manri N; Satake H; Kaneko A; Sakamoto T; Nishimura S
Chemistry; 2011 Feb; 17(8):2393-404. PubMed ID: 21264968
[TBL] [Abstract][Full Text] [Related]
14. Convergent total synthesis of a tumour-associated mucin motif.
Sames D; Chen XT; Danishefsky SJ
Nature; 1997 Oct; 389(6651):587-91. PubMed ID: 9335496
[TBL] [Abstract][Full Text] [Related]
15. Structure/activity studies of the anti-MUC1 monoclonal antibody C595 and synthetic MUC1 mucin-core-related peptides and glycopeptides.
Spencer DI; Missailidis S; Denton G; Murray A; Brady K; Matteis CI; Searle MS; Tendler SJ; Price MR
Biospectroscopy; 1999; 5(2):79-91. PubMed ID: 10217327
[TBL] [Abstract][Full Text] [Related]
16. An essential epitope of anti-MUC1 monoclonal antibody KL-6 revealed by focused glycopeptide library.
Ohyabu N; Hinou H; Matsushita T; Izumi R; Shimizu H; Kawamoto K; Numata Y; Togame H; Takemoto H; Kondo H; Nishimura S
J Am Chem Soc; 2009 Dec; 131(47):17102-9. PubMed ID: 19899793
[TBL] [Abstract][Full Text] [Related]
17. Synthetic glycopeptides for the development of cancer vaccines.
Liakatos A; Kunz H
Curr Opin Mol Ther; 2007 Feb; 9(1):35-44. PubMed ID: 17330400
[TBL] [Abstract][Full Text] [Related]
18. Diverse glycosylation of MUC1 and MUC2: potential significance in tumor immunity.
Irimura T; Denda K; Iida Si; Takeuchi H; Kato K
J Biochem; 1999 Dec; 126(6):975-85. PubMed ID: 10578046
[TBL] [Abstract][Full Text] [Related]
19. Immunology of O-glycosylated proteins: approaches to the design of a MUC1 glycopeptide-based tumor vaccine.
Hanisch FG; Ninkovic T
Curr Protein Pept Sci; 2006 Aug; 7(4):307-15. PubMed ID: 16918445
[TBL] [Abstract][Full Text] [Related]
20. The Development of Vaccines from Synthetic Tumor-Associated Mucin Glycopeptides and their Glycosylation-Dependent Immune Response.
Stergiou N; Urschbach M; Gabba A; Schmitt E; Kunz H; Besenius P
Chem Rec; 2021 Nov; 21(11):3313-3331. PubMed ID: 34812564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
